Related Experiment Video
Updated: May 12, 2025
The Use of Reverse Phase Protein Arrays RPPA to Explore Protein Expression Variation within Individual Renal Cell Cancers
Published on: January 22, 2013
Integrative PPI network and random forest analysis identifies KIF4A, TOP2A, and ASPM protein macromolecules as novel
Junkai Qin1, Dongjun Huang1, Chaobin Li1
1Department of Urology, Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning 530001, China.
Abstract:
The pathogenesis of kidney cancer is not fully understood, so there is an urgent need to identify new biomarkers to improve diagnosis and treatment. The study identified KIF4A, TOP2A and ASPM as novel protein biomarkers for renal cancer and explored their biological functions in the development and progression of renal cancer. A variety of bioinformatics methods were used to process and batch calibrate the transcriptome data of renal cancer. Differential gene expression analysis was performed using Limma packages, followed by functional enrichment analysis to identify biological pathways associated with kidney cancer. Construct a protein-protein interaction (PPI) network to prioritize core genes and use machine learning methods to further screen key signaling pathways. Epithelial-mesenchymal transition (EMT) marker score was used to evaluate the prognosis of renal carcinoma, and the results were validated by cell culture experiment. Integrated principal component analysis (PCA) showed significant effect of batch correction in the renal cancer cohort. Transcriptome analysis revealed dysregulation of conserved gene expression in renal carcinoma. Functional enrichment analysis showed that metabolic and immune signaling pathways play an important role in the pathogenesis of renal cancer. The integrated PPI network prioritized KIF4A, TOP2A and ASPM as key mitotic regulators and further confirmed these three as core carcinogenic drivers through machine learning. Finally, integrated prognostic analyses identified genetic features associated with EMT that are clinically significant.
Insights
Researchers identified KIF4A, TOP2A, and ASPM as novel protein biomarkers for kidney cancer (renal carcinoma). These key mitotic regulators are crucial for cancer progression and offer new diagnostic and therapeutic targets.
Area of Science:
- Oncology
- Molecular Biology
- Bioinformatics
Background:
- The precise mechanisms driving kidney cancer pathogenesis remain unclear, necessitating the discovery of novel biomarkers for improved diagnosis and treatment.
- Existing diagnostic and therapeutic strategies for renal carcinoma require enhancement through a deeper understanding of its molecular underpinnings.
Purpose of the Study:
- To identify and validate novel protein biomarkers for renal cancer.
- To investigate the biological roles of KIF4A, TOP2A, and ASPM in renal cancer development and progression.
- To explore metabolic and immune signaling pathways involved in kidney cancer pathogenesis.
Main Methods:
- Transcriptome data analysis using bioinformatics, including differential gene expression analysis (Limma) and functional enrichment.
- Construction of a protein-protein interaction (PPI) network to identify core genes.
- Application of machine learning methods for pathway screening.
- Evaluation of epithelial-mesenchymal transition (EMT) marker scores for prognostic assessment.
- Validation through cell culture experiments.
Main Results:
- KIF4A, TOP2A, and ASPM were identified as novel protein biomarkers for renal cancer.
- These three proteins function as key mitotic regulators and core carcinogenic drivers.
- Metabolic and immune signaling pathways were found to be significantly involved in kidney cancer pathogenesis.
- Genetic features associated with EMT were identified as clinically significant for prognosis.
Conclusions:
- KIF4A, TOP2A, and ASPM represent promising novel biomarkers for renal cancer diagnosis and therapy.
- Understanding the role of these mitotic regulators and EMT-associated genes can improve patient outcomes.
- Targeting metabolic and immune pathways may offer new therapeutic strategies for kidney cancer.
